StockData
Sigyn Therapeutics, Inc. logo

Sigyn Therapeutics, Inc. (SIGY) stock

SIGYOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025Score 0/30
$0.03+0.00 (0.00%)

Close on Oct 19, 2026Market cap $48.16KP/E –Yield –

Sigyn Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Sigyn Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2025 was $140.10K, down 84.3% year over year. For fiscal 2024 it was $773.28K, down 3.1% from the year before. The highest annual figure on record is $798.17K in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2024Dec 31, 2024$773.28K-3.1%
FY2023Dec 31, 2023$798.17K+21.4%
FY2022Dec 31, 2022$657.66K-10.4%
FY2021Dec 31, 2021$734.01K+75.0%
FY2020Dec 31, 2020$419.36K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2025Sep 30, 2025$29.68K-85.6%
Q2 FY2025Jun 30, 2025$7.48K-96.9%
Q1 FY2025Mar 31, 2025$8.84K-96.2%
Q4 FY2024Dec 31, 2024$94.10K-56.4%
Q3 FY2024Sep 30, 2024$206.16K-4.2%
Q2 FY2024Jun 30, 2024$240.43K+9.7%
Q1 FY2024Mar 31, 2024$232.59K+57.3%
Q4 FY2023Dec 31, 2023$215.93K+53.3%
Q3 FY2023Sep 30, 2023$215.23K+60.9%
Q2 FY2023Jun 30, 2023$219.16K+41.7%
Q1 FY2023Mar 31, 2023$147.84K-35.3%
Q4 FY2022Dec 31, 2022$140.86K-43.7%
Q3 FY2022Sep 30, 2022$133.77K-41.2%
Q2 FY2022Jun 30, 2022$154.68K+10.7%
Q1 FY2022Mar 31, 2022$228.34K+96.0%
Q4 FY2021Dec 31, 2021$250.26K-40.0%
Q3 FY2021Sep 30, 2021$227.50K–
Q2 FY2021Jun 30, 2021$139.74K–
Q1 FY2021Mar 31, 2021$116.52K+5790.6%
Q4 FY2020Dec 31, 2020$417.38K–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$1.98K–

More Sigyn Therapeutics figures

See a number that looks wrong?